TuHURA Biosciences
Open
$2.25
Prev. Close
$2.25
High
$2.25
Low
$2.24
Market Snapshot
$107.64M
-3.6
-0.38
22
TuHURA Biosciences, Inc. is a clinical-stage immuno-oncology company, which engages in the development of novel technologies to overcome resistance to cancer immunotherapy. The company is headquartered in Tampa, Florida and currently employs 19 full-time employees. The company went IPO on 2016-07-12. Its lead innate immune agonist, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. The company has initiated a single randomized placebo-controlled Phase III registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) compared to Keytruda plus placebo in first-line treatment for advanced or metastatic Merkel Cell Carcinoma. The company is leveraging its Delta Opioid Receptor technology to develop bi-specific antibody drug conjugates and antibody peptide conjugates targeting Myeloid Derived Suppressor Cells to inhibit their immune-suppressing effects on the tumor microenvironment to prevent T cell exhaustion and acquired resistance to checkpoint inhibitors and cellular therapies. The company is also focused on the novel VISTA inhibiting mAb, known as TBS-2025.
emptyResult
TuHURA Biosciences, Inc. is a clinical-stage immuno-oncology company, which engages in the development of novel technologies to overcome resistance to cancer immunotherapy. The company is headquartered in Tampa, Florida and currently employs 19 full-time employees. The company went IPO on 2016-07-12. Its lead innate immune agonist, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. The company has initiated a single randomized placebo-controlled Phase III registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) compared to Keytruda plus placebo in first-line treatment for advanced or metastatic Merkel Cell Carcinoma. The company is leveraging its Delta Opioid Receptor technology to develop bi-specific antibody drug conjugates and antibody peptide conjugates targeting Myeloid Derived Suppressor Cells to inhibit their immune-suppressing effects on the tumor microenvironment to prevent T cell exhaustion and acquired resistance to checkpoint inhibitors and cellular therapies. The company is also focused on the novel VISTA inhibiting mAb, known as TBS-2025.
Recently from Cashu
TuHURA Biosciences Appoints Amanda Garofalo as Senior VP of Clinical Operations
TuHURA Biosciences, Inc. recently fortifies its leadership team with the appointment of Amanda Garofalo, MSHS, as the new Senior Vice President of Clinical Operations. This decision comes as the immun…
TuHURA Biosciences Appoints Dr. Craig L. Tendler to Boost Oncology Development Efforts
TuHURA Biosciences Strengthens Leadership with Key Appointment in Oncology Development TuHURA Biosciences, Inc. is making significant strides in its pursuit of innovative cancer therapies as it announ…
TuHURA Biosciences Appoints Dr. Tendler to Elevate Leadership in Immuno-Oncology Development
TuHURA Biosciences Strengthens Leadership with Dr. Tendler's Expanded Role TuHURA Biosciences, a company specializing in immuno-oncology therapies, announces a significant leadership shift as Dr. Crai…
TuHURA Biosciences Innovates Immunotherapies to Overcome Cancer Treatment Resistance
TuHURA Biosciences Advances Cancer Treatment with Innovative Immunotherapies TuHURA Biosciences, Inc. is making significant strides in the field of immuno-oncology, as it seeks to address one of the m…